Patterns of use of sildenafil among commercially insured adults in the United States: 1998-2002

International Journal of Impotence Research

Volumn 16, Issue 4, 2004, Pages 313-318

  Delate, T ^a,b   Simmons, V A ^a   Motheral, B R ^a  

^a Express Scripts   (United States)

^b NONE   (United States)

Author keywords

Advertising; Pharmacoepidemiology; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; AGE; AGED; ARTICLE; DRUG MARKETING; DRUG USE; ERECTILE DYSFUNCTION; FEMALE; GENDER; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; ADVERTISING; AGE FACTORS; AGED; DATABASES, FACTUAL; DEATH, SUDDEN, CARDIAC; DRUG UTILIZATION; FEMALE; HUMANS; IMPOTENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; PIPERAZINES; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES; VASODILATOR AGENTS;

EID: 4644320538     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901191     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, 1994, pp 493-522.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-544.
3. Ragucci KR, Culhane NS. Treatment of female sexual dysfunction. Ann Pharmacother 2003; 37: 546-555.
4. Chew KK et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41-45.
5. Slag M et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736-1740.
6. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin N Am 1995; 22: 699-709.
7. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
8. Gingell C et al. Guidance on the management of erectile dysfunction in primary care. Prescriber 1999; 5(Suppl): 1-19.
9. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54-61.
10. Kaiser FE et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36: 511-519.
11. Mulligan T, Katz PG. Why aged men become impotent. Arch Intern Med 1989; 149: 1365-1366.
12. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997; 157: 2135-2138.
13. Jarow JP et al. Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609-1612.
14. Lamberg L. New drug for erectile dysfunction boon for many, 'viagravation' for some. JAMA 1998; 280: 867-869.
15. Viagra Package Insert. Available at: http://www.viagramd.com/ pi/proPackInsert.asp. Accessed July 21, 2003.
16. Kaplan SA et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481-486.
17. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled trial. Br J Obstet Gynaecol 2001; 108: 623-628.
18. Rosen RC. Sildenafil: medical advance or media event. Lancet 1998; 351: 1599-1600.
19. Braun M, Klotz T, Mathers MJ. 'Viagra Effect' -influence of mass media on patient behavior. Urol Int 2001; 66: 145-148.
20. Leland J. Ideas and Trends: Big Pharma Ogles Yasgur's Farm, The New York Times, 2001, July 29, Section 4 p 3.
21. Klein R, Sturm H. Viagra: a success story for rationing? Health Aff (Millwood) 2002; 21: 177-187.
22. Keith A. The economics of Viagra. Health Aff (Millwood) 2000; 19: 147-157.
23. Titlow K, Randel L, Clancy CM, Emanuel EJ. Drug coverage decisions: the role of dollars and values. Health Aff (Millwood) 2000; 19: 240-247.
24. Mitrany D. Lifestyle drugs: determining their value and who should pay. Pharmacoeconomics 2001; 19: 441-448.
25. Rosenthal MB et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346: 498-505.
26. Loyd L. Pharmaceutical Firms take Fight for Impotence Drug Users to the Mat. Philadelphia Inquirer, 2003, July 6, p. E01.
27. Lim PH, Moorthy P, Benton KG. The clinical safety of Viagra. Ann NY Acad Sci 2002; 962: 378-388.
28. Kloner RA. Viagra: what every physician should know. Ear Nose Throat J 1998; 77: 783-786.
29. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576-582, A7.
30. Harrold LR et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med 2000; 160: 3401-3405.
31. First DataBank (Medi-Span). Generic Product Identifier Number. First DataBank (Medi-Span): Indianapolis, IN, 2001.
32. McLeod AL, McKenna CJ, Northbridge DB. Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin Cardiol 2002; 25: 133-134.
33. Colfax GN et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001; 28: 373-379.
34. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989; 28: 577-582.
35. Ashworth M, Clement S, Wright M. Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice. Fam Pract 2002; 19: 236-241.
36. Wilson ECF et al. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics 2002; 20: 879-889.
37. Maguire P. How direct to consumer advertising is putting the squeeze on physicians. Available at: http://www.acponline.org/shell-cgi/printhappy.pl/ journals/news/mar99/squeeze.htm. Accessed July 22, 2003.
38. Lewis RW. Epidemiology of erectile dysfunction. Urol Clin N Am 2001; 28: 209-216.
39. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12(Suppl 4): S6-S11.